Abstract:Broadly neutralizing antibodies (bnAbs) recognizing a diversity of HIV-1 strains are widely thought to be essential for an HIV-1 vaccine. Extensive knowledge on bnAbs has been gained from studying natural HIV infection by following bnAb evolution in individual people with HIV (PWH). However, it remains essential to increase knowledge of bnAb responses in large PWH cohorts to assess the feasibility of inducing bnAb activity by vaccination. To allow a systematic analysis, we created the XbnAb cohort, a large bnAb-inducer cohort selected by screening plasma of PWH enrolled in the Swiss HIV Cohort Study (SHCS) and the Zurich Primary HIV Infection Study (ZPHI). The XbnAb cohort represents a retrospective, biobank-based cohort comprising data of 304 PWH who developed bnAb activity during HIV-1 infection. Here, we report on the characteristics of the XbnAb cohort and its potential for HIV vaccine research.

What problem does this paper attempt to address?

The problem this paper attempts to address is the feasibility of inducing broadly neutralizing antibody (bnAb) activity in a large population of HIV-1 infected individuals to support the development of an HIV vaccine. Specifically, the researchers created a large cohort named XbnAb by screening plasma samples from the Swiss HIV Cohort Study (SHCS) and the Zurich Primary HIV Infection Study (ZPHI), identifying 304 HIV-infected individuals who developed bnAb activity during natural infection. The establishment of this cohort aims to systematically analyze the immune response characteristics of these individuals, providing important references for future HIV vaccine design. ### Main Issues: 1. **Feasibility of assessing bnAb activity**: The researchers aim to understand the conditions and mechanisms that induce bnAb activity during natural infection by analyzing data from the large cohort. 2. **Supporting HIV vaccine development**: By systematically analyzing data from the XbnAb cohort, the researchers hope to provide scientific evidence for designing vaccines that can induce multiple bnAb activities. 3. **Identifying parameters influencing bnAb evolution**: The researchers aim to determine which viral, host, and disease factors are associated with bnAb evolution to better guide vaccine development. ### Research Background: - **Globally effective preventive HIV vaccine**: Currently, no effective vaccine has been developed that can completely prevent HIV transmission, which requires the induction of bnAb. - **Progress in bnAb research**: In recent years, immunogens derived from novel HIV-1 envelope glycoproteins have succeeded in inducing bnAb precursors, but complex immunization strategies are still needed to guide these precursors to develop into antibodies with broad neutralizing capacity and potency. - **bnAb response in natural infection**: Studying the polyclonal antibody response during natural infection can provide important clues for vaccine design. ### Research Methods: - **Cohort establishment**: By screening plasma samples from SHCS and ZPHI, 304 HIV-infected individuals who developed bnAb activity during natural infection were identified. - **Neutralization activity assessment**: The neutralization activity of plasma was assessed using a panel of multi-subtype HIV-1 envelope pseudoviruses, defining each participant's neutralization breadth and potency. - **Data analysis**: Through statistical analysis, the characteristics of the XbnAb cohort were compared with other participants to identify key factors influencing bnAb evolution. ### Conclusion: - **Representativeness of the XbnAb cohort**: The XbnAb cohort represents HIV-infected individuals who developed bnAb activity during natural infection, with characteristics consistent with previous research findings. - **Potential applications**: This cohort provides valuable resources for in-depth studies of bnAb evolution parameters, aiding the design and optimization of future HIV vaccines. In summary, by creating and analyzing the XbnAb cohort, this paper aims to assess the feasibility of inducing bnAb activity in a large population of HIV-infected individuals and provide scientific evidence for the development of HIV vaccines.

The XbnAb Cohort: 304 people with broadly neutralizing antibody activity to HIV-1

Immune Perturbations in HIV-1–infected Individuals Who Make Broadly Neutralizing Antibodies

A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses

Vaccination induces HIV broadly neutralizing antibody precursors in humans

Vaccination induces broadly neutralizing antibody precursors to HIV gp41

The Potential Of The Human Immune System To Develop Broadly Neutralizing Hiv-1 Antibodies: Implications For Vaccine Development

Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2

Preservation of memory B cell homeostasis in an individual producing broadly neutralising antibodies against HIV-1

Augmenting Neutralization Breadth Against Diverse HIV-1 by Increasing the Ab-Ag Interface on V2

A vaccine strategy for inducing broadly neutralizing antibodies against HIV

Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates

Tracing HIV-1 strains that imprint broadly neutralizing antibody responses

HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen

Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals

Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques

Targeted selection of HIV-specific antibody mutations by engineering B cell maturation

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site

Immunization of cows with HIV envelope trimers generates broadly neutralizing antibodies to the V2-apex from the ultralong CDRH3 repertoire

Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth

Identification and specificity of broadly neutralizing antibodies against HIV